Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus

Diabetes/Metabolism Reviews

Volumn 12, Issue 1, 1996, Pages 37-56

  Lewis, Gary F ^a,c   Steiner, George ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ATHEROSCLEROSIS; HUMAN; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 0029946192     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199603)12:1<37::AID-DMR154>3.3.CO;2-H     Document Type: Review

References (203)

1. Pyörrälä K, Laakso M, and Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3: 463-524, 1987.
2. Reaven GM: Syndrome X:6 years later. J Int Med 236 (Suppl 736): 13-22, 1994.
3. Wilson PWF, Kannel WB, and Anderson KM: Lipids, glucose intolerance and vascular disease: the Framingham study. Manogr Atheroscler 13: 1-11, 1985.
4. Assmann G and Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116: 1713-1724, 1988.
5. Stern MP and Haffner SM: Dyslipidemia in type II diabetes: implications for therapeutic intervention. Diabetes Care 14: 1144-1159, 1991.
6. Stamler J, Vaccaro O, Neaton JD, and Wentworth D: Diabetes, other risk factors and 12 yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16: 434-444, 1993.
7. Garcia MJ, McNamara PM, Gordon T, and Kannel WB: Morbidity and mortality in diabetes in the Framingham population: sixteen year follow-up study. Diabetes 23: 105-111, 1994.
8. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, and Prick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15: 820-825, 1992.
9. Wingard DL, Barrett-Connor E, Criqui MH, and Suarez L: Clustering of heart disease risk factors in diabetes compared to non-diabetic adults. Am J Epidemiol 177: 19-26, 1983.
10. Laakso M, Lehto S, Penttilä I, and Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88: 1421-1430, 1993.
11. Clusitupa MIJ, Niskanen LK, Siitonen O, Vohtilainen E, and Pyörälä K: Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36: 1175-1184, 1993.
12. Fontbonne A, Eschwege E, Cambien F, Richard J-L, Ducimetiere P, Thibult N, Warnet J-M, Claude J-R and Rosselin G-E: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 300-304, 1989.
13. Barrett-Connor E and Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 118: 489-961, 1983.
14. West KM, Ahuja MMS, Bennett PH, Czyzyk A, De-Acosta OM, and Fuller JH: The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 6: 361-369, 1983.
15. Austin MA: Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 129: 249-259, 1989. ;
16. Castelli WP: The triglyceride issue: a view from Framingham. Am Heart J 112: 432-437, 1986.
17. Manninen V, Tenkanen L, Koskinen P, Huttunen PC, Mantarri M, Heinionen OP, and Prick MH: Joint effects of triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary risk in the Helsinki Heart Study: implications for treatment. Circulation 85: 37-45, 1992.
18. Assman G and Schulte H: Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70: 733-737, 1992.
19. Steiner G: The dyslipoproteinemias of diabetes. Atherosclerosis 110: S27-33, 1994.
20. Berr F: Characterization of chylomicron remnant clearance by retinyl palmitate label in normal humans. J Lipid Res 33: 915-930, 1992.
21. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 60: 473-485, 1979.
22. Bradley WA and Gianturco SH: Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations. J Int Med 236 (Suppl 736): 33-39, 1994.
23. Packard CJ, Munro A, Lorimer AR, Gotto AM, and Shepherd J: Metabolism of apolipoprotein B in large triglyceride-rich lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 74: 2178-2192, 1984.
24. Gianturco SH, Bradley WA, Gotto AM Jr, Morrisett JD, and Peavy DL: Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest 70: 168-178, 1982.
25. Stender S and Zilversmit DB: Transfer of plasma lipoprotein into aortas of cholesterol-fed rabbits: molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis I: 38-49, 1981.
26. Nordestgaard BG: Atherogenesis in diabetic cholesterol-fed rabbits. Dan Med Bull 38: 1-8, 1991.
27. Arnon R, Sehayek E, Vogel T, and Eisenberg S: Effects of exogenous apo E-3 and of cholesterol-enriched meals on the cellular metabolism of human chylomicrons and their remnants. Biochim Biophys Ada 1085: 336-342, 1991.
28. Sehayek E and Eisenberg S: The role of native apolipoprotein B-containing lipoproteins in atherosclerosis: cellular mechanisms. Curr Opin Lipidol 5: 350-353, 1994.
29. Witztum J and Steinberg D: Role of oxidized low density lipoproteins in atherogenesis. J Clin Invest 88: 1785-1792, 1991.
30. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
31. Hiramatsu K and Arimori S: Increased superoxide production by mononuclear cells of patients with hypertriglyceridemia and diabetes. Diabetes 37: 832-837, 1988.
32. Deslypere J-P: Modified lipoproteins in diabetes. J Int Med 236 (Suppl 736): 69-74, 1994.
33. Curtiss LK and Witztum JL: Plasma apolipoproteins A-l, A-2, B, C-l and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 34: 452-461, 1985.
34. Klein RL, Lyons TJ, and Lopes-Virella MF. Inter- action of very-low-density Hpoprotein isolated from type 1 (insulin-dependent) diabetic subjects with human monocyte-derived macrophages. Metabolism 38: 1108-1114, 1989.
35. Kasama T, Yoshino G, Iwatani I, Iwai M, Hatanaka H, Kazumi T, Oimonir M, and Baba S: Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulin dependent diabetics. Atherosclerosis 63: 263-266, 1987.
36. Poapst M, Reardon M, and Steiner G: Relative contribution of triglyceride-rich lipoproteins particle size and number to plasma triglyceride concentration. Arteriosclerosis 5: 381-390, 1985.
37. Reardon MF and Steiner G: The use of kinetics in investigating metabolism of very low density and intermediate density lipoprotein. In Lipoprotein Kinetics and Modelling, Berman M, Grundy SM, and Howard BV (Eds). Academic Press, New York, 99-112, 1982.
38. Steiner G, Schwartz L, Shumak S, and Poapst M: The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 75: 124-130, 1987.
39. Reardon MF, Nestel PJ, Craig IH, and Harper RW: Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 71: 881-888, 1985.
40. Groot PHE, Van Stiphout WAHJ, Kraus XH, Jansen H, Van Toi A, Van Ramshorst E, Chin-On S, Hofrnan A, Cresswell SR, and Havekes L: Human lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11: 653-662, 1991.
41. Simpson HS, Williamson CM, Olivecrona T, Pringle S, MacLean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, and Shepherd J: Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85: 193-202, 1990.
42. Patsch JR, Miesenbrock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr and Patsch W: Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 12: 1336-1345, 1992.
43. Cohn JS: Postprandial lipid metabolism. Curr Opin Lipidol 5: 185-190, 1994.
44. Havel RJ: Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5: 102-109, 1994.
45. Ginsberg HN, Blaner W, Jones J, Thomas A, Sharrett AR, and Begg M: Postprandial lipemia is a predictor of the presence of coronary heart disease in males but not females (Abstract). Circulation 88: 1-363, 1993.
46. Ryu JE, Howard G, Craven TE, Bond MG, Hagmari AP, and Grouse J III: Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 23: 823-828, 1992.
47. Karpe F, Bard J-M, Steiner G, Carlson LA, Fruchart J-C, and Hamsten A: HDLs and alimentary lipemia studies in men with previous myocardial infarction at a young age. Arterioscler Thromb 13: 11-22, 1993.
48. Lewis GF, O'Meara NM, Soltys PA, Blackman TD, Cabana VG, Iverius PH, Pugh WL, Druetzler AF, Lukens JR, Getz GS, and Polonsky KS: Fasting hypertriglyceridemia in non-insulin-dependent diabetes mellitus (NIDDM) is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72: 934-944, 1991.
49. Chen Y-DI, Swami S, Skowronski R, Coulston A, and Reaven GM: Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76: 172-177, 1993.
50. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D, and Jacotot B: Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 43: 270-278, 1994.
51. Syvanne M, Hilden H, and Taskinen MR: Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res. 35: 15-26, 1994.
52. Lewis GF, O'Meara NM, Soltys PA, Blackman TD, Iverius PH, Druetzler AF, Getz GS, and Polonsky KS: Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the Vitamin A fat-loading test. J Clin Endocrinol Metab 71: 1041-1050, 1990.
53. Karpe F, Steiner G, Olivecrona T, Carlson LA, and Hamsten A: Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 91: 748-758, 1993.
54. Schneeman BO, Kotite L, Todd KM, and Havel RJ: Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B48 and B100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA 90: 2069-2073, 1993.
55. Patsch JR, Prasad S, Gotto AM Jr, and Patsch W: High density lipoprotein 2: relationship of the plasma level of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80: 341-347, 1987.
56. O'Meara NM, Lewis GF, Cabana VG, Iverius PH, Getz GS, and Polonsky KS: Role of basal triglyceride and high density lipoprotein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab 75: 465-471, 1992.
57. Ooi TC, Simo E, and Yakichuk JA: Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb 12: 1184-1190, 1992.
58. Edelstein C, Fredenrich C, Schuelke JC, Jensen WE, Sitrin M, Iverius PH, and Scanu AM: Hypoalphalipoproteinemia: postprandial response of subjects with preprandial normotriglyceridemia and hypertriglyceridemia to various diets, Metabolism 42:247-257, 1993.
59. 14-labelled chylomicra from dog plasma. J Clin Invest 35: 1025-1032, 1956.
60. Boden G, Chen X, Desantis RA, and Kendrick Z: Effects of insulin on fatty acid reesterification in healthy subjects. Diabetes 42: 1588-1593, 1993.
61. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk MJ, Potts JL, and Hockaday TDR: Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 41: 264-272, 1992.
62. Roust LR and Jensen MD: Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 42: 1567-1573, 1993.
63. Lewis GF, O'Meara NM, Cabana VG, Blackman JD, Pugh WL, Druetzler AF, Lukens JR, Getz GS, and Polonsky KS: Postprandial triglyceride response in type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycemic control or level of postprandial insulin replacement. Diabetologia 34: 253-259, 1991.
64. Lewis GF, Uffelman KD, Szeto L, Weller B, and Steiner G. Interaction between free fatty acids (FFA) and insulin in the acute control of very low density lipoprotein (VLDL) production in humans. J Clin Invest 95: 158-166, 1995.
65. Chen Y-DI, Swami S, Skowronski R, Coulston AM, and Reaven GM: Effect of variations in dietary fat and carbohydrate intake on postprandial lipemia in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 76: 347-351, 1993.
66. Jeppesen J, Zhou M-Y, Chen Y-DI, and Reaven GM: Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia 37: 781-787, 1994.
67. Jeppesen J, Zhou M-Y, Chen Y-DI, and Reaven GM: Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 17: 1093-1099, 1994.
68. Syvänne M, Vuorinen-Markkpla H, Hilden H, and Taskinen M-R: Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 13: 286-295, 1993.
69. Howard BV, Knowler WC, Vasquez B, Kennedy AL, Pettitt DJ, and Bennet PH: Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population: comparison of diabetics and non-diabetics. Arteriosclerosis 4: 462-471, 1988.
70. Barrett-Connor E, Grundy SM, and Holdbrook MJ: Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 115: 657-663, 1982.
71. Barrett-Connor E, Witztum JL, and Holdbrook M: A community study of high density lipoproteins in adult non-insulin-dependent diabetics. Am J Epidemiol 117: 186-192, 1983.
72. Gordon DJ and Rifkind BM: High-density lipo- protein: the clinical implications of recent studies. N Engl J Med 321: 1311-1316, 1989.
73. Karhapää P, Malkki M, and Laakso M: Isolated low HDL cholesterol: an insulin resistant state. Diabetes 43: 411-417, 1994.
74. Schaefer EJ, Levy RI, Anderson DW, Banner RN, Brewer HB Jr, and Blackwelder WC: Plasma triglycerides in regulation of HDL-cholesterol levels. Lancet ii: 391-392, 1978.
75. Deckelbaum RJ, Granot E, Oschry Y, Rose L, and Eisenberg S: Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4: 225-231, 1984.
76. Nikkila EA, Taskinen MR, and Sane T: Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. Am Heart J 113: 543-548, 1987.
77. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 11: 2-14, 1991.
78. Richards EG, Grundy SM, and Cooper K: Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol 63: 1214-1220, 1989.
79. Davis CE, Gordon D, LaRosa J, Wood PDS, and Halperin M: Correlations of plasma high density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. Circulation 62: IV-24-IV-30, 1980.
80. Albrink MJ, Krauss RM, Lindgren FT, von der Groeben J, Pan S, and Wood WD: Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids 15: 688-678, 1980.
81. Phillips NR, Havel RJ, and Kane JP: Serum apolipoprotein A-I levels: relationship to lipoprotein lipid levels and selected demographic variables. Am J Epidemiol 116: 302-313, 1982.
82. Tribble DL and Krauss RM: HDL and coronary artery disease. Adv Intern Med 38: 1-29, 1993.
83. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, and Sacks F: Effects of postmenppausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325: 1196-1204, 1991.
84. Johansson J, Walldius G, and Carlson LA: Close correlation between high-density lipoprotein and triglycerides in normotriglyceridemia. J Int Med 232: 43-51, 1992.
85. Lewis GF, Cabana VG, Uffelman KD, Steiner G, Polonsky KS, and Getz GS: Production of small HDL particles after intravenous heparin in hypertriglyceridemic diabetic and non-diabetic individuals: studies before and after gemfibrozil therapy (Abstract). Atherosclerosis 109(1,2): 224, 1994.
86. Chang LBF, Hopkins GJ, and Barter PJ: Particle size distribution of high density lipoproteins as a function of plasma triglyceride concentration in human subjects. Atherosclerosis 56: 61-70,1985.
87. Jackson RL, Barnhart RL, and Kashyap ML: Characterization of high density lipoproteins from patients with severe HTG. Atherosclerosis 66: 37-43, 1987.
88. Sparks DL, Frohlich J, Lacko AG, and Pritchard PH: Relationship between cholesteryl ester transfer activity and high density lipoprotein composition in hyperlipidemic patients. Atherosclerosis 77: 183-191, 1989.
89. Tall AR: Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest 86: 379-384, 1990.
90. Patsch JR, Karlin JB, Scott LW, Smith LC, and Gotto AM Jr: Inverse relationship between blood levels of high density lipoprotein subtraction 2 and magnitude of post-prandial lipemia. Proc Natl Acad Sci USA 80: 1449-1453, 1983.
91. Patsch JR, Prasad S, Gotto AM, and Bengtsson-Olivecrona G: Postprandial lipemia, a key for the conversion of high density lipoprotein 2 into high density lipoproteins 3 by hepatic lipase. J Clin Invest 74: 2017-2023, 1984.
92. Yen FT, Deckelbaum RJ, Mann CJ, Marcel YL, Milne RW, and Tall AR: Inhibition of cholesteryl ester transfer protein by monoclonal antibody: effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest 83: 2018-2024, 1989.
93. Barter PJ and Jones ME: Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J Lipid Res 21: 238-249, 1980.
94. Groot PH, Scheeck LM, and Jansen H: Liver lipase and high-density lipoprotein: lipoprotein changes after incubation of human serum with rat liver lipase. Biochim Biophys Acta 751: 393-400, 1983.
95. Clay MA, Newnham HH, and Barter PJ: Hepatic lipase promotes a loss of apolipoprotein A- 1 from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb 11: 415-422, 1991.
96. Kuusi T, Saarinen P, and Nikkila E A: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Atherosclerosis 36: 589-593, 1980.
97. Shirai K, Barnhart RL, and Jackson RL: Hydrolysis of human plasma high density lipoprotein 2 phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun 100: 591-599, 1981,
98. Newnham HH, Hopkins GJ, Devlin S and Barter PJ: Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma. Atherosclerosis 82: 167-176, 1990.
99. Newnham HH and Barter PJ: Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipae. Biochim Biophys Acta 1125: 297-304, 1992.
100. Kuusi T, Ehnholm C, Viikari J, Harkonen R, Vartiainen E, Puska P, and Taskinen MR: Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res 30: 1117-1126, 1989.
101. Kuusi T, Saarinen P, and Nikkila EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Atherosclerosis 36: 589-593, 1980.
102. Applebaum-Bowden D, Haffner SM, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, and Hazzard WR: Postheparin plasma triglyceride lipases: relationships with very low density lipoprotein triglyceride and high density lipoprotein 2 cholesterol. Arteriosclerosis 5: 273-282, 1985.
103. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, and Breslow JL: Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: studies in transgenic mice. J Clin Invest 92: 1143-1152, 1993.
104. Brinton EA, Eisenberg S, and Breslow JL: Increased apo A-I and apo A-II fractional catabolic rate in patients with low HDL-C levels with or without hypertriglyceridemia. J Clin Invest 87: 536-544, 1991.
105. Goldberg IJ, Blaner WS, Vanni TM, Moukides M, and Ramakrishnan R: Role of lipoprotein lipase in the regulation of high density-lipoprotein apolipoprotein metabolism: studies in normal and lipoprotein-lipase inhibited monkeys. J Clin Invest 86: 463-473, 1990.
106. Ramakrishnan R and Ginsberg HN: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91: 1743-1752, 1993.
107. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 5: 339-349, 1994.
108. Austin M, Hokanson JE, and Brunzell JD: Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 5: 395-403, 1994.
109. Coresh J, Kwiterovich PO Jr, Smith HH, and Bachorik PS: Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34: 1687-1697, 1993.
110. Luc G, de Gennes JL, and Chapman MJ: Further resolution and comparison of the heterogeneity of plasma low density lipoproteins in human hyperlipoproteinemias: type in hyperlipoproteinemia, hypertriglyceridemia and familial hypercholesterolemia. Atherosclerosis 71: 143, 1988.
111. McNamara JR, Jenner JL, Li Z, Wilson PWF, and Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 12: 1284-1290, 1992.
112. Krauss RM, Williams PT, Lindgren FT, and Wood PD: Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men. Arteriosclerosis 8: 155-162, 1988.
113. Austin MA, King MC, Vranizan KM, and Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82: 495-506, 1990.
114. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, and Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small dense low-density lipoprotein particles. J Clin Invest 92: 141-146, 1993.
115. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP Jr, Mayer EJ, and Krauss RM: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 88: 381-387, 1993.
116. Haffner SM, Mykkänen L, Valdez RA, Paidi M, Stern MP, and Haward BV: LDL size and subclass pattern in a biethnic population. Arterioscler Thromb 13: 1623-1630, 1993.
117. Barakat HA, McLendon VD, Marks R, Pories W, Health J, and Carpenter JW: Influence of morbid obesity and non-insulin-dependent diabetes mellitus on high-density lipoprotein composition and subpopulation distribution. Metabolism 41: 37-41, 1992.
118. Feingold KR, Grunfeld C, Pang M, Doerrler W, and Krauss RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb 12: 1496-1502, 1992.
119. Stewart MW, Laker MF, Dyer RG, Game F, Mitcheson J, Winocour PH, and Alberti KGMM: Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb 13: 1046-1052, 1993.
120. Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA, and Hamsten A: Composition of human low density lipoprotein: effects of postprandial triglyceride rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis 98: 33-49, 1993.
121. Nicoll A, and Lewis B: Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man. Eur J Clin Invest 10: 487, 1980.
122. Zambon A, Austin MA, Brown BG, Hokanson JE, and Brunzell JD: Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 13: 147-153, 1993.
123. Auwerx JH, Marzetta CA, Hokanson JE, and Brunzell JD: Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 9: 319-325, 1989.
124. Breckenridge WC, Little JA, Alaupovic P, Wang CS, Kuksis A, Kakis G, Lindgren F, and Gardiner G: Lipoprotein abnormalities associated with familial deficiency of hepatic lipase. Atherosclerosis 45: 161, 1982.
125. Gambert P, Bouzerand-Gambert C, Athias A, Farnier M, and Lallemant C: Human low density lipoprotein subfractions separated by gradient gel electrophoresis: composition, distribution and alterations induced by cholesteryl ester transfer protein. J Lipid Res 31: 1199-1210, 1990.
126. Griffin BA and Packard CJ: Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 5: 200-206, 1994.
127. de Graaf J, Hak-Lemmers HLM, Hectors MFC, Demacker PNM, Hendriks JCM, and Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfractions in healthy subjects. Arteriosclerosis 11: 298-306, 1991.
128. Tribble DL, Roll LG, Wood PD, and Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93: 189-199, 1992.
129. Ghait A, Brazg RL, Tribble DL, and Krauss RM: Susceptibility of small, dense low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94: 350-356, 1993.
130. Dejager S, Bruckert E, and Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 34: 295-308, 1993.
131. Chen GC, Liu W, Duchateau P, Allaart J, Hamilton RL, Mendel CM, Lau K, Hardman DA, Frost PH, Malloy MJ, and Kane JP: Cohformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). J Biol Chem 269: 29121-29128, 1994.
132. Dreon DM, Ferstrom HA, Miller B, and Krauss RM: Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 8: 121-126, 1994.
133. Nevin D, Schwartz RS, and Brunzell D: Evidence that central obesity modulates genetic expression of low density lipoprotein subclass phenotype B (abstract). Diabetes 43 (Suppl 1): 35, 1994.
134. Williams FT, Krauss RM, Wood PD, Lindgren FT, Giotas C, and Vranizan KM: Lipoprotein subfractions of runners and sedentary men. Metabolism 35: 45-52, 1986.
135. Williams PT, Krauss RM, Vranizan KM, Labers JJ, Terry RB, and Woods PDS: Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. Arteriosclerosis 9: 623-632, 1989.
136. Superko HR and Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95: 69-76, 1992.
137. Franceschini G, Bernini F, Michelagnoli S, Bellosta S, Vaccarino V, Funagalli R, and Sirtori CR: Lipoprotein changes and increased affinity of LDL for their receptors after acipomox treatment in hypertriglyceridemia. Atherosclerosis 81: 41-49, 1990.
138. De Graaf J, Hendriks JCM, Demacker PNM, and Stalenhoef AFH: Identification of multiple dense LDL subfractions with enhanced susceptibility to in-vitro oxidation among hypertriglycerid- emic subjects: normalization after clofibrate treatment. Arterioscler Thromb 13: 712-719, 1993.
139. Yuan J, Tsai MY, Hegland J, and Hunninghake DB: Effects of fluvastatin (XU 62-320), an HMG-COA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87: 147-157, 1991.
140. Lahdenperä S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, and Taskinen MR: Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 16: 584-592, 1993.
141. Bruckert E, Dejager S, and Chapman MJ: Ciprofibrate therapy normalises the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 100: 91-102, 1993.
142. Hokanson JE, Austin MA, Zambon A, and Brunzell JD: Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 13: 427-434, 1993.
143. Gill J: The pathophysiology and epidemiology of myocardial infarction: a review. Drugs 42 (Suppl 2): 1-7, 1991.
144. Maclsaac AI, Thomas JD, and Topol EJ: Toward the quiescent coronary plaque. J Am Coll Cardiol 22: 1228-1241, 1993.
145. Hamsten A, Karpe F, Bavenholm P, and Silveira A: Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J Int Med 236 (Suppl 736): 75-88, 1994.
146. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, and Thamson SG: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet ii: 533-537, 1986.
147. Carvalho de Sousa J, Bruchert E, Giral B, et al: Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study. Haemostasis 19: 83-90, 1989.
148. Dalaker K, Smith P, Arnesen H, and Prydz H: Factor VII-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 222: 111-116, 1987.
149. Donders SHJ, Lustermans FAT, and Van Wersch JWJ: Coagulation factors and lipid composition of blood in treated and untreated hypertensive patients. Scand J Clin Lab Invest 53: 179-186, 1993.
150. Folsom AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, and Wu KK: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other haemostatic factors in moderately overweight adults. Arteroscler Thromb 13: 162-169, 1993.
151. Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, and Cruickshank JK: Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 76: 203-208, 1989.
152. Moor E, Hamsten A, Karpe F, Båvenholm P, Blombäck M, and Silveira A: Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 71: 707-712, 1994.
153. Ostermann H and Van De Loo J: Factors of the haemostasis system in diabetic patients: a survey of controlled studies. Haemostasis 16: 386-416, 1986.
154. Miller GJ, Martin JC, Mitropoulas KA, Reeves BEA, Thompson RL, Meade TW, Cooper JA, and Cruikshank JK: Plasma factor VII is activated by postprandial triglyceridemia, irrespective of dietary fat composition. Atherosclerosis 86: 163-171, 1991.
155. Marckmann P, Sandström B, and Jespersen J: Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. Atherosclerosis 101: 225-234, 1993.
156. Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E, Pietinen P, Korhonen H, Kuulasmaa K, and Ehnholm C. The effects of saturated fat and N-6 polyunsaturated fat on postprandial lipemia and haemostatic activity. Atherosclerosis 103: 1-11, 1993.
157. Silveira A, Karpe F, Blombäck M, Steiner G, and Hamsten A: Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 14: 60-69, 1994.
158. Pacy PJH, Mitropoulos KA, Venkatesan S, Watts GF, Reeves BEA, and Halliday D: Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. Atherosclerosis 103: 231-243, 1993.
159. Mitropoulos KA, Miller GJ, Watts GF, and Durrington PN: Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 94: 119-125, 1992.
160. Mitropoulos KA: Lipoprotein metabolism and thrombosis. Curr Opin Lipidol 5: 227-235, 1994.
161. Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, and Cooper J: Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration. Arterioscler Thromb 14: 214-222, 1994.
162. Bradley WA, Gianturco SH: Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost 14: 253-257, 1988.
163. Carvalho de Sousa J, Brucker E, Giral P, Sonia C, Chapman J, Truffert J, Dairou F, de Germes JL and Caen JP: Coagulation factor VII and plasma triglycerides: decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 19: 125-130, 1989.
164. Carvalho de Sousa, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, and Caen JP: Association between coagulation factors VII and X with triglyceride-rich lipoproteins. J Clin Pathol 41: 940-944, 1988.
165. Hamsten A, Wiman B, de Faire U, and Blombäck M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557-1563, 1985.
166. Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de Faire U, and Mettinger L: Haemostatic function in myocardial infarction. Br Heart J 55: 58-66, 1986.
167. Hamsten A, de Faire U, Waldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, and Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii: 3-9, 1987.
168. Simpson HDR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, and Woolf L: Hypertriglyceridemia and hypercoagulability. Lancet i: 786-790, 1983.
169. Wiman B and Hamsten A: Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 34: 179-192, 1991.
170. Asplund-Carlson A, Hamsten A, Wiman B, and Carlson LA: Relationship between plasma plasminogen activator inhibitor-I activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridemia men. Diabetologia 36: 817-825, 1993.
171. Stiko-Rahm A, Wiman B, Hamsten A, and Nilsson J: Secretion of plasminogen activator inhibitor-I from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10: 1067-1073, 1990.
172. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, and Tremoli E: Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 12: 19-25, 1992.
173. Raccah D, Alessi MC, Scelles V, Menard C, Juhan-Vague I, and Vague P: Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. Fibrinolysis 7: 171-176, 1993.
174. Juhan-Vague I, Alessi MC, and Vague P: Increased plasma plasminogen activator inhibitor I levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34: 457-462, 1991.
175. Juhan-Vague I, Thompson SG, Jespersen J, and the ECAT Angina Pectoris Study Group: Involvement of the haemostatic system in the insulin-resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb 13: 1865-1873, 1993.
176. 2. Thromb Haemostas 60: 491-494, 1988.
177. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, and Princen HMG: Plasminogen activator inhibitor I: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 62: 723-728, 1989.
178. Schneider DJ and Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease by hyperinsulinemic states. Proc Natl Acad Sci USA 88: 9959-9963, 1991.
179. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, and Meinders AE: The cardiovascular risk factor plasminogen activation inhibitor-I is related to insulin resistance. Metabolism 42: 945-949, 1993.
180. Gris JC, Schved JF, Feugeas O, Aguilar-Martinez P, Arnaud A, Sanches N, and Sarlat G: Impact of smoking, physical training and weight reduction on FVII, PAI-1 and haemostatic markers in sedentary men. Thromb Haemost 64: 516-520, 1990.
181. Folsam AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller L, and Wu KK: Impact of weight loss on plasminogen activator inhibitor-I (PAI-1), factor VII and other haemostatic factors in moderately overweight adults. Arterioscler Thromb 13: 162-169, 1993.
182. Vague P, Juhan-Vague I, Alessi M, Badier C, and Valadier J: Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in nondiabetic obese subjects. Thromb Haemost 57: 326-328, 1987.
183. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, and Gagnon DR: Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 120: 672-676, 1990.
184. Landin K, Tengborn L, and Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227: 273-278, 1990.
185. Aimèr L-O and Kjellström T: The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 61: 81-85, 1986.
186. Olefsky JM, Farquahr JW, and Reaven GM: Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 20: 470-475, 1974.
187. Steiner G and Vranic M: Hyperinsulinemia and hypertriglyceridemia, a vicious cycle with atherogenic potential. Int J Obes 6 (Suppll): 117-124, 1982.
188. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14: 1132-1143, 1991.
189. Bonora E, Zavaroni I, Bruschi F, Alpi O, Pezzarossa A, Guerra L, Dall'Aglio E, Coscelli C, and Butturini U: Peripheral hyperinsulinemia of simple obesity: pancreatic hypersecretion of impaired insulin metabolism? J Clin Endocrinol Metab 59:1121-1127, 1984.
190. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, and Van Cauter E: Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81: 435-441, 1988.
191. Steiner G, Morita S, and Vranic M: Resistance to insulin but not to glucagon in lean human hypertriglyceridemics. Diabetes 29: 899-905, 1980.
192. McKane WR, Stevens AB, Andrews WJ, Henry RW, and Bell PM: The assessment of hepatic and peripheral insulin insensitivity in hypertriglyceridemia. Metabolism 39: 1240-1245, 1990.
193. Zuniga-Guarjardo S, Steiner G, Shumack S, and Zinman B: Insulin resistance and action in hypertriglyceridemia. Diabetes Res Clin Pract 14: 55-61, 1991.
194. Bruce R, Godsland I, Walton C, Crook D, and Wynn V: Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 43: 1275-1281, 1994.
195. Sheu WH, Shieh SM, Fuh MM, Shen DD, Jeng CY, Chen YD, and Reaven GM: Insulin resistance, glucose intolerance, and hyperinsulinemia: hypertriglyceridemia versus hypercholesterolemia. Arterioscler Thromb 13: 367-370, 1993.
196. Laws A, Stefanick ML, and Reaven GM: Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69: 343-347, 1989.
197. Sane T and Taskinen M-R: Does familial hyper- triglyceridemia predispose to NIDDM? Diabetes Care 16:1494-1501, 1993.
198. Steiner G: Altering triglyceride concentrations change insulin-glucose relationships in hypertriglyceridemic patients: a double-blind study with implications for atherosclerosis. Diabetes Care 14: 1077-1081, 1991.
199. Vuorinen-Markkola H, Yki-Jarvinen H, and Taskinen MR: Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 161-169, 1993.
200. Steiner G: Insulin and hypertriglyceridernia. In Diabetes 1979, Waldhausl WK (Ed). Excerpta Medica, Amsterdam, 1979, pp 590-593.
201. Bieger WP, Michel G, Barwich D, Biehl K, and Wirth A: Diminished insulin receptors on monocytes and erythrocytes in hypertriglyceridernia. Metabolism 33: 982-987, 1984.
202. Randle PJ, Garland PB, Hales CN, and Newsholme EA. The glucose-fatty acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i: 785-789: 1963.
203. DeFronzo RA and Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.